The Omicron variant optimizes RBD mutations of the RBM, strengthening its binding force with the host angiotensin converting enzyme-2 (ACE-2) and enhancing its infectivity, making it difficult to neutralize with most antibodies produced by vaccinations or previous infections (Chen and Wei, 2022). The gene discussed is ACE2; the disease is infection.